DURHAM, NC, and LIEGE, BELGIUM - April 4, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the launch of an equity offering by means of a private placement to certain investors, with the intention to raise an amount of approximately € 6 million. The size of the placement may be increased, however. The board of directors has cancelled the preferential subscription right of the existing shareholders in the framework of this transaction.

Kempen & Co and Nomura Code Securities are acting as joint lead managers and joint bookrunners and ING Belgium acts as co-lead manager for the private placement, which shall be structured as an accelerated bookbuilding process to establish the offer price and final size of the placement. The accelerated bookbuilding process shall start with immediate effect and is expected, barring unforeseen circumstances to close on April 5, subject to acceleration or extension of the timetable.

The net proceeds of the private placement will be used, in order of priority (subject to the size of the placement), to accelerate product development in line with the new business strategy and to set up a CLIA laboratory and hire a sales and marketing team in the US.

The new shares will be admitted to listing and will be fungible with the existing shares on NYSE Euronext Brussels following their issuance and the publication of the approved listing prospectus. The company has requested the Financial Services and Markets Authority to suspend its shares from trading on NYSE Euronext Brussels and NYSE Euronext Amsterdam pending the placement. Trading in the stock is expected to resume following the publication of the results of the placement.

The company will announce the results of the offering as soon as possible after closing of the bookbuilding in a subsequent press release.

About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University and Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Pfizer, and other industry leaders. More information can be found on the Company website: www.mdxhealth.com or on twitter at the following address : www.twitter.com/mdxhealth.